scholarly journals Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma

2021 ◽  
Vol 10 (5) ◽  
pp. 1745-1758
Author(s):  
Hyehyun Jeong ◽  
Hyeon‐Su Im ◽  
Yeonghak Bang ◽  
Yong‐Hee Kim ◽  
Hyeong Ryul Kim ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Squamous Cell ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Definitive Chemoradiotherapy

scholarly journals Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology

1999 ◽  
Vol 80 (8) ◽  
pp. 1281-1288 ◽  
Author(s):  
Y Shimada ◽  
M Imamura ◽  
G Watanabe ◽  
S Uchida ◽  
H Harada ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Molecular Biology ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Oesophageal Squamous Cell Carcinoma

Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma

2018 ◽  
Vol 106 (3) ◽  
pp. 255-262 ◽  
Author(s):  
B.‐Y. Wang ◽  
S.‐C. Wu ◽  
H.‐C. Chen ◽  
W.‐H. Hung ◽  
C.‐H. Lin ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Neoadjuvant Chemoradiotherapy ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Definitive Chemoradiotherapy

Clinical Outcomes and Prognostic Factors of Patients With Esophageal Squamous Cell Carcinoma With Oligo-recurrence Treated With Radical Re-irradiation

2020 ◽  
Vol 40 (4) ◽  
pp. 2387-2392
Author(s):  
CHEN-YUAN LIN ◽  
HSIN-YUAN FANG ◽  
MING-YU LEIN ◽  
CHING-CHAN LIN ◽  
LI-YUAN BAI ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Squamous Cell

scholarly journals Peri-treatment peripheral blood cell score predicts long-term locoregional progression hazard in oesophageal squamous cell carcinoma after definitive chemoradiotherapy

2019 ◽  
Author(s):  
Jianzhou Chen ◽  
Liangyu Xu ◽  
Hong Guo ◽  
Ruihong Huang ◽  
Longjia Guo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Oesophageal Cancer ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Tumour Progression ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Definitive Chemoradiotherapy

Abstract Background Prediction of response to chemoradiotherapy is critical for the optimal management of oesophageal cancer, yet it is still an unmet clinical need. This study aims to evaluate the predictive potential of peri-treatment peripheral blood cells (PBC) in disease progression hazard in oesophageal cancer following chemoradiotherapy.Methods 87 patients with primary oesophageal squamous cell carcinoma were subjected to definitive concurrent chemoradiotherapy in a phase II trial. PBC parameters (haemoglobin, neutrophils, platelets, lymphocytes and monocytes) were collected at 7 time points through the course of radiotherapy. The values of peri-treatment PBC parameters in predicting 3-year cumulative hazard of tumour progression were evaluated.Results Patients with disease progression displayed distinct distribution patterns of peri-treatment PBC compared to patients without. Greater prediction capabilities for risk of locoregional disease progression were found in PBC collected after the start of radiotherapy compared to their pretreatment counterparts, and in individual parameters rather than cell-to-cell ratios. The most predictive PBC parameters were integrated by summation and designated as a PBC score (PBCS), which further augmented their predictive power. Patients divided according to their PBCS (high vs medium vs low) had significantly different 3-year cumulative hazards of locoregional progression (58% vs 29% vs 7%, P = 0.0017). Multivariate analysis confirmed that PBCS high (HR 12.2, 95%CI 2.0-76.3, P = 0.007) and medium (HR 5.8, 95%CI 1.2-27.7, P = 0.028) are independent indicators of locoregional progression.Conclusion Peri-treatment PBCS can predict the long-term hazard of locoregional progression after definitive chemoradiotherapy in patients with oesophageal squamous cell carcinoma.

scholarly journals Peri-treatment peripheral blood cell score predicts long-term locoregional progression hazard in oesophageal squamous cell carcinoma after definitive chemoradiotherapy

2020 ◽  
Author(s):  
Liangyu Xu ◽  
Jianzhou Chen ◽  
Hong Guo ◽  
Ruihong Huang ◽  
Longjia Guo ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Oesophageal Cancer ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Tumour Progression ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Definitive Chemoradiotherapy

Abstract Background: Prediction of response to chemoradiotherapy is critical for the optimal management of oesophageal cancer, yet it is still an unmet clinical need. This study aims to evaluate the predictive potential of peri-treatment peripheral blood cells (PBC) in disease progression hazard in oesophageal cancer following chemoradiotherapy.Methods: 87 patients with primary oesophageal squamous cell carcinoma were subjected to definitive concurrent chemoradiotherapy in a phase II trial. PBC parameters (haemoglobin, neutrophils, platelets, lymphocytes and monocytes) were collected at 7 time points through the course of radiotherapy. The values of peri-treatment PBC parameters in predicting 3-year cumulative hazard of tumour progression were evaluated.Results: Patients with disease progression displayed distinct distribution patterns of peri-treatment PBC compared to patients without. Greater prediction capabilities for risk of locoregional disease progression were found in PBC collected after the start of radiotherapy compared to their pretreatment counterparts, and in individual parameters rather than cell-to-cell ratios. The most predictive PBC parameters were integrated by summation and designated as a PBC score (PBCS), which further augmented their predictive power. Patients divided according to their PBCS (high vs medium vs low) had significantly different 3-year cumulative hazards of locoregional progression (58% vs 29% vs 7%, P = 0.0017). Multivariate analysis confirmed that PBCS high (HR 12.2, 95%CI 2.0-76.3, P = 0.007) and medium (HR 5.8, 95%CI 1.2-27.7, P = 0.028) are independent indicators of locoregional progression.Conclusion: Peri-treatment PBCS can predict the long-term hazard of locoregional progression after definitive chemoradiotherapy in patients with oesophageal squamous cell carcinoma.

Prognostic Factors of Salvage Esophagectomy for Residual or Recurrent Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy

2018 ◽  
Vol 42 (9) ◽  
pp. 2887-2893 ◽  
Author(s):  
Yuki Kiyozumi ◽  
Naoya Yoshida ◽  
Takatsugu Ishimoto ◽  
Taisuke Yagi ◽  
Yuki Koga ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Definitive Chemoradiotherapy ◽  
Salvage Esophagectomy

scholarly journals Association Between Cancer Cachexia and Prognosis in Patients with Head and Neck Squamous Cell Carcinoma Who Received Chemoradiotherapy

2021 ◽  
Author(s):  
Naomi Hayashi ◽  
Yasuyoshi Sato ◽  
Yu Fujiwara ◽  
Naoki Fukuda ◽  
Xiaofei Wang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cancer Cachexia ◽  
Neck Squamous Cell Carcinoma ◽  
Adjuvant Chemoradiotherapy ◽  
Adjuvant Setting ◽  
Definitive Chemoradiotherapy

Abstract Objectives: This retrospective observational study is conducted to evaluate the association between cancer cachexia and prognosis in head and neck cancer patients treated with chemoradiotherapy using skeletal muscle mass index at the level of the third lumbar vertebra with computed tomography.Methods: Two hundred forty-two patients were enrolled and categorized into the following four groups based on cancer cachexia criteria and treatment setting: definitive chemoradiotherapy with cachexia, definitive chemoradiotherapy without cachexia, adjuvant chemoradiotherapy with cachexia, and adjuvant chemoradiotherapy without cachexia. Progression-free survival (PFS) and overall survival (OS) between cachexia and non-cachexia groups were compared by treatment setting using the long-rank test. Prognostic factors were evaluated using the Cox proportional hazards model.Results: Fifty patients were diagnosed with cancer cachexia (20.7%). In the definitive setting, both PFS and OS were significantly shorter in the cachexia group (median PFS, 15.5 months vs. not reached, p < 0.01; median OS, 48.4 months vs. not reached. p < 0.01). Conversely, there was no significant difference between the two groups in the adjuvant setting. UICC Stage IV, base of albumin of <4, and cachexia were significant poor prognostic factors in the definitive setting. However, no prognostic factors were detected in the adjuvant setting.Conclusion: Cancer cachexia was negatively related with prognosis in patients with head and neck squamous cell carcinoma who received definitive chemoradiotherapy. Nutritional intervention during chemoradiotherapy may improve survival in these patients. Further research is warranted.

Sign in / Sign up

Export Citation Format

Share Document